Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Subject Understanding of the Risks Associated With ZYBAN®, WELLBUTRIN®, WELLBUTRIN SR®, and WELLBUTRIN XL®

NCT03001440 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03001440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03001440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Subject Understanding of the Risks Associated With ZYBAN®, WELLBUTRIN®, WELLBUTRIN SR®, and WELLBUTRIN XL®
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
October 7, 2016
Completion date
December 28, 2016
Enrollment
1 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major